BLOOD AND BODY DEFENCE Dr. Amel Eassawi Dr. Abdelrahman Mustafa 1.
Dr. Abdelrahman Elsingergy (Regional Product Manager) PORT GHALEB 4th Feb …. Abdelrahman...
Transcript of Dr. Abdelrahman Elsingergy (Regional Product Manager) PORT GHALEB 4th Feb …. Abdelrahman...
Dr. Abdelrahman Elsingergy
(Regional Product Manager)
PORT GHALEB 4th Feb 2015
SPIMACO ADDWAEIH
Saudi Pharmaceutical Industries & Medical Appliances Co.
Introduction
Saudi Pharmaceutical Industries & Medical Appliances Corporation (SPIMACO) is a Saudi Joint–Stock company ,established in 1986.
SPIMACO is the only Saudi Pharmaceutical
Company listed and quoted in the Saudi Stock Market.
In order to meet its future expansion plans,
SPIMACO has increased its capital by 30%, to produce more products that serve its
community .
SPIMACO ADDWAEIH is committed to provide high quality pharmaceutical products meeting international standards that earn the loyalty of its regional and international customers through Internal Development and Strategic Alliances to benefit its society.
Mission
Therapeutic Classes
• SPIMACO manufactures & markets more than 250 Products in various markets to cover wide range of therapeutic areas:
NSAIDs Analgesics Antibiotics Erectile Dysfunction Anti-Diabetics
Antihypertensives Anti- Hyperlipidemics Anti-Allergics Heamatinics Anti-Ulceratives Other GIT products
SPIMACO ADDWAEIH
Major Strengths
State of Art Al-Qassim Pharmaceutical Plant is located Northwest of Riyadh.
150,000m2 is dedicated to Production and the rest for Warehousing, Labs, Product Development and Administrative activities.
Manufacturing Capabilities
Manufacturing Capabilities
• SPIMACO is known to exceed international standards and high levels of manufacturing and quality employing state-of-the art manufacturing facilities.
• SPIMACO is implementing SAP system which makes it the only pharmaceutical company to employ such advanced system regionally.
• SPIMACO is ISO (ISO 9001 - 2000 and ISO 14000 Environmental Management System) certified Company.
King Fahad & King Abdul Aziz Quality Awards
Environment Compliance Certificate.
Manufacturing Capabilities
FDA used Spimaco facility as a training model for Saudi MOH officials & has ranked SPIMACO as among the top ten in the region due to the high standard of its design and the powerful GMP quality system implemented in the plant.
Manufacturing Capabilities
Certified
• Strategic decision was made very early to establish a nucleus for a research center focusing on the sophisticated field of Biotechnology.
• The unit is an extension to a joint research program with King Abdulaziz City for Science and Technology (KACST).
• This unit was furnished under the guidance of Good
Laboratory Practice (GLP). Qualified research scientists and technical staff were carefully selected.
• All the required production and laboratory equipments were sourced from the well-known European, US and Canadian manufactures for biotech equipment.
• Expertise of a European corporation specialized in this field was obtained.
Biotech Unit
SPIMACO ADDWAEIH Existing Major Business Alliances
SPIMACO Major Alliances
FULL MARKETING LICENSES
CO-MARKETING LICENSE
SPIMACO Major Alliances
MANUFACTURING UNDER-LICENSE
BRAND ACQUISITION
Snafi (2nd brand of CIALIS)
o Klavox (2nd brand of AUGMENTIN)
•Lorine (2nd brand of CLARITINE) •Neorin (2nd brand of AERIUS) •Lorinase Syrup
o Hymox (2nd brand of AMOXIL)
Out Licensing
•Sitagliptin (2nd brand of Januvia) •Etirocoxib (2nd brand of Arcoxia) •Montelukast (2nd brand of Singulair)
Fevadol Range
Verine
Otricold
Clarinase Syp
Recormon
Ceclor & Keflex
DISTRIBUTION ALLIANCE
Biotech Unit
Spimaco Footprint in MENA Region
Spimaco Footprint in MENA Region
65 Sales and
Marketing staff
90 Sales and
Marketing staff
15 Sales and
Marketing staff
16 Sales and
Marketing staff
• 6 Sales and
Marketing staff
• 33 Sales and
Marketing staff
• 6 Sales and
Marketing staff
234 Sales and
Marketing staff
• 5 Sales and
Marketing staff
• 16 Sales and
Marketing staff
12 Sales and
Marketing staff
More than 500 Sales &
Marketing Staff,
SPIMACO Has one of
The largest Sales
forces In the MENA
region
SPIMACO ADDWAEIH Updated Sales Report
Updated Sales Report YTD 2’2013
SPIMACO ranks the 1st position in Saudi Pharma (Private) market, as
per own products with 56.9% growth
Also, SPIMACO ranks the 1st position in Saudi Pharma ( Private) Market,
as per sales include Licensors’ products with 53.3% growth
SPIMACO grew by 50.1Mio SR
Source : IMS –SAPI- 2’13
Top 10 Manufacturers, YTD 2’2013
Saudi Pharma Market (Private)
0
20
40
60
80
100
120
140
Va
lue
Mio
SR
+56.9%
+12.6%
-3.1%
+31.4% -8.2%
+8.5%
+25.8%
+18%
+11.9%
+43.9%
Spimaco Own Products Only
Growth%
MS% 7.8% 6.3% 3.7% 4.7% 4.6% 4.1% 3.2% 2.7% 2.4% 2.2%
Value mil SR 138.3 112.1 101.8 83 82 72.4 56.7 47.3 43 38.4
Top 10 Manufacturers, Spimaco occupies the first rank with 53.3% Growth and 9% MS
0
20
40
60
80
100
120
140
160
Spimaco Tabuk GSK Julphar Pfizer Jamjoom Novartis Astra MSD Aventis
Va
lue
Mio
SR
+53.3%
+12.6%
-3.1%
+31.4% -8.2%
+8.5%
+25.8
% +18%
+11.9
% +43.9
%
Growth%
MS% 9% 6.3% 5.7% 4.7% 4.6% 4.1% 3.2% 2.7% 2.4% 2.2%
Value mil SR 159.8 112.1 101.8 83 82 72.4 56.7 47.3 43 38.4
Spimaco Products including Licensors
Top 10 Leading Products By Value
0
5
10
15
20
25
30
35
40
45
50
Growth%
Mio
SR
MS% 2.7% 1.1% 0.9% 0.8% 0.7% 0.7% 0.7% 0.7% 0.6% 0.6%
Value mil SR 46.9 18.8 15 13.9 13.1 12.9 11.8 11.5 11.4 11.1
+308.3%
+22.1%
SPIMACO has 2 products out of 10
SPIMACO 2011 NEWS
Spimaco acquired a 48% stake in Eirgen
Pharma
Spimaco acquired a 48% stake in
Eirgen Pharma
A LISTED Saudi Arabian company has acquired a 48 per cent stake in Waterford-based pharmaceutical firm EirGen for €19 million.
Saudi Pharmaceutical Industries and Medical Appliances Corp (Spimaco) is one of the largest pharmaceutical companies in the Middle East. The Riyadh-based company, which had previously indicated its intention to expand into Europe, is listed on the Saudi stock exchange.
EirGen’s products are already licensed throughout Europe, the United States, Canada and, most recently, Japan, a key advantage for the company, which hopes to increase its presence in global markets.
The company sells its products across 45 countries and has partnerships with pharmaceutical companies across the world, including in South African, Uruguay, and across Europe.
SPIMACO ADDWAEIH is committed to provide high quality pharmaceutical products meeting international standards that earn the loyalty of its regional and international customers through internal development and strategic alliances to benefit its society.
Mission
THANK YOU
Abdelrahman Elsingergy
Regional Product Manager
SPIMACO ADDWAEH
PORT GHALEB 4th Feb 2015
• Over 16 years history for 340 Mio. Patients worldwide
• Gold standard for many types of infections especially UTIs
• 100,000 Patients enrolled for trials all over the world
• Minimal bacterial resistance in spite of geographical magnitude of the
problem
-International Journal of Urology .July.2004
Ciprofloxacin – SCOOP
1. Binding to bacterial enzyme DNA gyrase , and
consequently inhibiting DNA replication and transcription
2. Destroys the bacterial cell envelope, resulting in quick
bacterial death
Mode of Action
Cystitis
Cystitis
Cystitis
Pyelonephritis
Prostatitis
250 mg 17 L.E.
500 mg 33 L.E.
750 mg 40 L.E.
Algeria Libya
Egypt
Lebanon
KSA
Kuwait
Bahrain Qatar
UAE
Oman
A Growing International Brand in 10 countries
THANK YOU